Patents by Inventor Toshihide KURIHARA

Toshihide KURIHARA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220402994
    Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 22, 2022
    Inventors: Toshihide Kurihara, Yusaku Katada, Kazuo Tsubota, Hideki Kandori
  • Publication number: 20220323516
    Abstract: An object of the present invention is to provide a composition for preventing visual dysfunction caused by exposure to light, such as so-called blue light. The present invention provides a composition comprising a lactic acid bacterium as an active ingredient for use in suppressing or improving conditions caused by retinal inflammation resulting from light damage. Eye discomfort is an exemplary condition caused by retinal inflammation resulting from light damage.
    Type: Application
    Filed: June 13, 2022
    Publication date: October 13, 2022
    Applicant: Kirin Holdings Kabushiki Kaisha
    Inventors: Toshihide KURIHARA, Yuji MORITA, Kenta JONAI, Daisuke FUJIWARA
  • Publication number: 20220273761
    Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.
    Type: Application
    Filed: April 28, 2022
    Publication date: September 1, 2022
    Inventors: Toshihide Kurihara, Yusaku Katada, Kazuo Tsubota, Hideki Kandori
  • Patent number: 11389494
    Abstract: An object of the present invention is to provide a composition for preventing visual dysfunction caused by exposure to light, such as so-called blue light. The present invention provides a composition comprising a lactic acid bacterium as an active ingredient for use in suppressing or improving conditions caused by retinal inflammation resulting from light damage. Eye discomfort is an exemplary condition caused by retinal inflammation resulting from light damage.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: July 19, 2022
    Assignee: Kirin Holdings Kabushiki Kaisha
    Inventors: Toshihide Kurihara, Yuji Morita, Kenta Jonai, Daisuke Fujiwara
  • Publication number: 20220025018
    Abstract: Provided are a chimeric protein of two types of rhodopsins, an ion-transporting rhodopsin and a G protein-coupled receptor rhodopsin, and a nucleic acid encoding the same, for the prevention and suppression of progression of retinal diseases, the improvement in visual cognitive behavioral functions (e.g., improvement in light-dark determination functions, improvement in bright spot evading functions, and/or crisis avoidance functions), and the enhancement of visual functions (e.g., improvement in visual acuity). The present invention also provides a method for preventing or suppressing the progression of a disease, disorder or symptom of the retina, for improving a visual cognitive behavioral function (e.g., improvement in light-dark determination functions, improvement in bright spot evading functions, and/or crisis avoidance functions), or for enhancing visual functions (e.g.
    Type: Application
    Filed: January 18, 2019
    Publication date: January 27, 2022
    Inventors: Toshihide Kurihara, Yusaku Katada, Kazuo Tsubota
  • Publication number: 20210228901
    Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 29, 2021
    Applicants: TOSHIBA MATERIALS CO., LTD., TSUBOTA LABORATORY, INC.
    Inventors: Masahiko YAMAKAWA, Hidemasa TORII, Toshihide KURIHARA, Kazuo TSUBOTA
  • Patent number: 11007375
    Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: May 18, 2021
    Assignees: Toshiba Materials Co., Ltd., Tsubota Laboratory, Inc.
    Inventors: Masahiko Yamakawa, Hidemasa Torii, Toshihide Kurihara, Kazuo Tsubota
  • Publication number: 20210000343
    Abstract: A device for supporting diagnosis has: a reception unit that is configured to receive a fundus image of a subject eye; an identification unit provided with a trained model that is configured to recognize, in the fundus image of the subject eye, an area of abnormality in blood circulation, wherein the model has been trained based upon an image of a fundus and an area of abnormality in blood circulation specified in a fluorescent angiography image of the fundus; and an output unit that is configured to output information relating to the area of abnormality in blood circulation recognized in the fundus image of the subject eye.
    Type: Application
    Filed: July 16, 2020
    Publication date: January 7, 2021
    Applicant: NIKON CORPORATION
    Inventors: Toshihide KURIHARA, Yusaku KATADA, Kazuo TSUBOTA, Kanato MASAYOSHI
  • Patent number: 10866433
    Abstract: An optical element has a transmission spectrum characterized in that a local maximum falls within a wavelength region longer than 315 nm but shorter than or equal to 400 nm, a local minimum falls within a wavelength region longer than or equal to 380 nm but shorter than or equal to 500 nm, and the wavelength at the local maximum is shorter than the wavelength at the local minimum.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: December 15, 2020
    Assignees: JINS HOLDINGS Inc., Tsubota Laboratory, Inc.
    Inventors: Shunsuke Shioya, Kazuo Tsubota, Toshihide Kurihara, Hidemasa Torii
  • Patent number: 10865134
    Abstract: A wavelength-selective transmissive glass has a light transmittance Tmore than 315 nm and 400 nm or less at a wavelength of more than 315 nm and 400 nm or less represented by the formula shown below of 1% or more in terms of a plate thickness of 6 mm and a light transmittance T315 nm or less at a wavelength of 315 nm or less represented by the formula shown below of 60% or less in terms of a plate thickness of 6 mm. Ak is a weighting factor at a wavelength k (nm) for calculating T (light transmittance) defined in ISO-9050:2003, and Tk is a transmittance at the wavelength k (nm) in terms of a plate thickness of 6 mm: Tmore than 315 nm and 400 nm or less=(?k=more than 315400Ak×Tk)/(?k=more than 315400Ak) T315 nm or less=(?k=300315Ak×Tk)/(?k=300315Ak).
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: December 15, 2020
    Assignees: AGC Inc., TSUBOTA LABORATORY, INC.
    Inventors: Kensuke Nagai, Tetsuya Nakashima, Yutaka Kuroiwa, Hiroyuki Hijiya, Masamichi Tanida, Akio Koike, Manabu Nishizawa, Kazuo Tsubota, Toshihide Kurihara, Hidemasa Torii
  • Patent number: 10823982
    Abstract: The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. Or, the myopia treatment device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: November 3, 2020
    Assignee: TSUBOTA LABORATORY, INC.
    Inventors: Kazuo Tsubota, Kazuno Negishi, Hidemasa Torii, Toshihide Kurihara
  • Publication number: 20200171112
    Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.
    Type: Application
    Filed: May 15, 2018
    Publication date: June 4, 2020
    Inventors: Kazuo TSUBOTA, Toshihide KURIHARA
  • Publication number: 20200150457
    Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.
    Type: Application
    Filed: September 5, 2019
    Publication date: May 14, 2020
    Applicant: TSUBOTA LABORATORY, INC.
    Inventors: Shinichi IKEDA, Xiaoyan JIANG, Kazuo TSUBOTA, Toshihide KURIHARA
  • Publication number: 20190374587
    Abstract: An object of the present invention is to provide a composition for preventing visual dysfunction caused by exposure to light, such as so-called blue light. The present invention provides a composition comprising a lactic acid bacterium as an active ingredient for use in suppressing or improving conditions caused by retinal inflammation resulting from light damage. Eye discomfort is an exemplary condition caused by retinal inflammation resulting from light damage.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 12, 2019
    Applicant: Kirin Holdings Kabushiki Kaisha
    Inventors: Toshihide KURIHARA, Yuji MORITA, Kenta JONAI, Daisuke FUJIWARA
  • Publication number: 20190365760
    Abstract: Novel HIF inhibitors having low cytotoxicity and suitable for ophthalmologic treatment and agents for the treatment or prevention of ischemic diseases, glaucoma, optic nerve diseases, retinal degenerative diseases, retinal degenerative diseases, angiogenic retinal diseases, cancer, neurodegenerative or autoimmune diseases are provided. The present invention is a therapeutic or prophylactic agent for ischemic disease, glaucoma, optic nerve disease, retinal degenerative disease, retinal degenerative disease, angiogenic retinal disease, cancer, neurodegenerative disease, or autoimmune disease, which comprises as an active ingredient one or more or an extract thereof selected from the group consisting of plants belonging to the genus Asian, plants belonging to the genus Swiss, plants belonging to the genus Grape, plants belonging to the genus Brassica, fish belonging to the genus Kivinago, and so on.
    Type: Application
    Filed: November 14, 2017
    Publication date: December 5, 2019
    Inventors: Toshihide KURIHARA, Yukihiro MIWA, Kazuo TSUBOTA, Hiroyoshi INOUE
  • Publication number: 20190194294
    Abstract: The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 27, 2019
    Inventors: Toshihide Kurihara, Yusaku Katada, Hiromitsu Kunimi, Kazuo Tsubota, Hideki Kandori
  • Publication number: 20190129204
    Abstract: The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. Or, the myopia treatment device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia.
    Type: Application
    Filed: October 9, 2018
    Publication date: May 2, 2019
    Applicant: TSUBOTA LABORATORY, INC.
    Inventors: Kazuo Tsubota, Kazuno Negishi, Hidemasa Torii, Toshihide Kurihara
  • Publication number: 20180351050
    Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.
    Type: Application
    Filed: July 25, 2018
    Publication date: December 6, 2018
    Applicants: TOSHIBA MATERIALS CO., LTD., TSUBOTA LABORATORY, INC.
    Inventors: Masahiko Yamakawa, Hidemasa Torii, Toshihide Kurihara, Kazuo Tsubota
  • Publication number: 20180341122
    Abstract: An optical element has a transmission spectrum characterized in that a local maximum falls within a wavelength region longer than 315 nm but shorter than or equal to 400 nm, a local minimum falls within a wavelength region longer than or equal to 380 nm but shorter than or equal to 500 nm, and the wavelength at the local maximum is shorter than the wavelength at the local minimum.
    Type: Application
    Filed: November 25, 2015
    Publication date: November 29, 2018
    Applicants: JINS INC., Tsubota Laboratory, Inc.
    Inventors: Shunsuke Shioya, Kazuo Tsubota, Toshihide Kurihara, Hidemasa Toril
  • Patent number: 10133092
    Abstract: The purpose of the present invention is to provide a myopia prevention device. A myopia prevention device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia. Further, a myopia prevention device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: November 20, 2018
    Assignee: TSUBOTA LABORATORY, INC.
    Inventors: Kazuo Tsubota, Kazuno Negishi, Hidemasa Torii, Toshihide Kurihara